Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole
Summary Aim : To compare the pharmacokinetics and pharmacodynamics of lansoprazole 30 mg administered intravenously in 0.9% NaCl or in polyethylene glycol, or orally. Methods : Twenty‐nine subjects received lansoprazole orally on days 1–7 and intravenous lansoprazole in NaCl on days 8–14. Blood samp...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2004-05, Vol.19 (10), p.1111-1122 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1122 |
|---|---|
| container_issue | 10 |
| container_start_page | 1111 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 19 |
| creator | Freston, J. W. Pilmer, B. L. Chiu, Y.‐L. Wang, Q. Stolle, J. C. Griffin, J. S. Lee, C. Q. |
| description | Summary
Aim : To compare the pharmacokinetics and pharmacodynamics of lansoprazole 30 mg administered intravenously in 0.9% NaCl or in polyethylene glycol, or orally.
Methods : Twenty‐nine subjects received lansoprazole orally on days 1–7 and intravenous lansoprazole in NaCl on days 8–14. Blood samples were collected on days 1, 7, 8 and 14. Fasting basal acid output and pentagastrin‐stimulated maximal acid output were determined on days −1, 8, 9 and 15. Thirty‐six different subjects received one of four regimen sequences: intravenous lansoprazole in NaCl, intravenous in polyethylene glycol, per orally, or intravenous placebo, each for 5 days. Twenty‐four hour intragastric pH was recorded on days 1 and 5.
Results : Intravenous and per oral lansoprazole for 7 days produced equivalent basal acid output and maximal acid output suppression. Pharmacokinetics and mean pH values with intravenous lansoprazole in NaCl or polyethylene glycol were equivalent. Both produced mean pH and percentages of time pH above 3, 4, 5 and 6 that were significantly greater than did per orally.
Conclusions : Intravenous lansoprazole inhibits acid secretion as effectively in NaCl as in polyethylene glycol, and its onset of action is faster than per oral lansoprazole. |
| doi_str_mv | 10.1111/j.1365-2036.2004.01942.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71924686</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71924686</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4452-6c2f05de367dce4ac4276dac0a87fbde72eed5ffae2a230b4e6d6d34f7bca63c3</originalsourceid><addsrcrecordid>eNqNkMtOwzAQRS0EoqXwCygb2CX4FaddsKgQLwkJJGBtTeyxmpJHsdNC-XoSWhWWeGNrfGbm6hASMZqw7lzMEyZUGnMqVMIplQllE8mTzz0y3H3skyHlahLzMRMDchTCnFKqMsoPyYClTHJO2ZA8X6-gXEJbNHXUuKidYbSYga_ANG9FjW1hQgS13RXtuoaqL3ZwUbceVlg3yxCVUIdm4eGrKfGYHDgoA55s7xF5vbl-ubqLHx5v76-mD7GRMuWxMtzR1KJQmTUowUieKQuGwjhzucWMI9rUOUAOXNBcorLKCumy3IASRozI-WbuwjfvSwytropgsOyyYJdJZ2zCpRqrDhxvQOObEDw6vfBFBX6tGdW9UD3XvTfde9O9UP0jVH92rafbHcu8QvvbuDXYAWdbAIKB0nmoTRH-cJmSqps7Ipcb7qMocf3vAHr69NK_xDe6S5Pl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71924686</pqid></control><display><type>article</type><title>Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole</title><source>MEDLINE</source><source>IngentaConnect Free/Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Freston, J. W. ; Pilmer, B. L. ; Chiu, Y.‐L. ; Wang, Q. ; Stolle, J. C. ; Griffin, J. S. ; Lee, C. Q.</creator><creatorcontrib>Freston, J. W. ; Pilmer, B. L. ; Chiu, Y.‐L. ; Wang, Q. ; Stolle, J. C. ; Griffin, J. S. ; Lee, C. Q.</creatorcontrib><description>Summary
Aim : To compare the pharmacokinetics and pharmacodynamics of lansoprazole 30 mg administered intravenously in 0.9% NaCl or in polyethylene glycol, or orally.
Methods : Twenty‐nine subjects received lansoprazole orally on days 1–7 and intravenous lansoprazole in NaCl on days 8–14. Blood samples were collected on days 1, 7, 8 and 14. Fasting basal acid output and pentagastrin‐stimulated maximal acid output were determined on days −1, 8, 9 and 15. Thirty‐six different subjects received one of four regimen sequences: intravenous lansoprazole in NaCl, intravenous in polyethylene glycol, per orally, or intravenous placebo, each for 5 days. Twenty‐four hour intragastric pH was recorded on days 1 and 5.
Results : Intravenous and per oral lansoprazole for 7 days produced equivalent basal acid output and maximal acid output suppression. Pharmacokinetics and mean pH values with intravenous lansoprazole in NaCl or polyethylene glycol were equivalent. Both produced mean pH and percentages of time pH above 3, 4, 5 and 6 that were significantly greater than did per orally.
Conclusions : Intravenous lansoprazole inhibits acid secretion as effectively in NaCl as in polyethylene glycol, and its onset of action is faster than per oral lansoprazole.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/j.1365-2036.2004.01942.x</identifier><identifier>PMID: 15142201</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>2-Pyridinylmethylsulfinylbenzimidazoles ; Administration, Oral ; Anti-Ulcer Agents - administration & dosage ; Anti-Ulcer Agents - pharmacokinetics ; Anti-Ulcer Agents - pharmacology ; Biological and medical sciences ; Chlorates ; Cross-Over Studies ; Digestive system ; Drug Carriers ; Ethylene Glycol ; Female ; Gastric Acid - secretion ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Infusions, Intravenous ; Lansoprazole ; Male ; Medical sciences ; Omeprazole - administration & dosage ; Omeprazole - analogs & derivatives ; Omeprazole - pharmacokinetics ; Omeprazole - pharmacology ; Pharmacology. Drug treatments</subject><ispartof>Alimentary pharmacology & therapeutics, 2004-05, Vol.19 (10), p.1111-1122</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4452-6c2f05de367dce4ac4276dac0a87fbde72eed5ffae2a230b4e6d6d34f7bca63c3</citedby><cites>FETCH-LOGICAL-c4452-6c2f05de367dce4ac4276dac0a87fbde72eed5ffae2a230b4e6d6d34f7bca63c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2036.2004.01942.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2036.2004.01942.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15764620$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15142201$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Freston, J. W.</creatorcontrib><creatorcontrib>Pilmer, B. L.</creatorcontrib><creatorcontrib>Chiu, Y.‐L.</creatorcontrib><creatorcontrib>Wang, Q.</creatorcontrib><creatorcontrib>Stolle, J. C.</creatorcontrib><creatorcontrib>Griffin, J. S.</creatorcontrib><creatorcontrib>Lee, C. Q.</creatorcontrib><title>Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Aim : To compare the pharmacokinetics and pharmacodynamics of lansoprazole 30 mg administered intravenously in 0.9% NaCl or in polyethylene glycol, or orally.
Methods : Twenty‐nine subjects received lansoprazole orally on days 1–7 and intravenous lansoprazole in NaCl on days 8–14. Blood samples were collected on days 1, 7, 8 and 14. Fasting basal acid output and pentagastrin‐stimulated maximal acid output were determined on days −1, 8, 9 and 15. Thirty‐six different subjects received one of four regimen sequences: intravenous lansoprazole in NaCl, intravenous in polyethylene glycol, per orally, or intravenous placebo, each for 5 days. Twenty‐four hour intragastric pH was recorded on days 1 and 5.
Results : Intravenous and per oral lansoprazole for 7 days produced equivalent basal acid output and maximal acid output suppression. Pharmacokinetics and mean pH values with intravenous lansoprazole in NaCl or polyethylene glycol were equivalent. Both produced mean pH and percentages of time pH above 3, 4, 5 and 6 that were significantly greater than did per orally.
Conclusions : Intravenous lansoprazole inhibits acid secretion as effectively in NaCl as in polyethylene glycol, and its onset of action is faster than per oral lansoprazole.</description><subject>2-Pyridinylmethylsulfinylbenzimidazoles</subject><subject>Administration, Oral</subject><subject>Anti-Ulcer Agents - administration & dosage</subject><subject>Anti-Ulcer Agents - pharmacokinetics</subject><subject>Anti-Ulcer Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Chlorates</subject><subject>Cross-Over Studies</subject><subject>Digestive system</subject><subject>Drug Carriers</subject><subject>Ethylene Glycol</subject><subject>Female</subject><subject>Gastric Acid - secretion</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Lansoprazole</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Omeprazole - administration & dosage</subject><subject>Omeprazole - analogs & derivatives</subject><subject>Omeprazole - pharmacokinetics</subject><subject>Omeprazole - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtOwzAQRS0EoqXwCygb2CX4FaddsKgQLwkJJGBtTeyxmpJHsdNC-XoSWhWWeGNrfGbm6hASMZqw7lzMEyZUGnMqVMIplQllE8mTzz0y3H3skyHlahLzMRMDchTCnFKqMsoPyYClTHJO2ZA8X6-gXEJbNHXUuKidYbSYga_ANG9FjW1hQgS13RXtuoaqL3ZwUbceVlg3yxCVUIdm4eGrKfGYHDgoA55s7xF5vbl-ubqLHx5v76-mD7GRMuWxMtzR1KJQmTUowUieKQuGwjhzucWMI9rUOUAOXNBcorLKCumy3IASRozI-WbuwjfvSwytropgsOyyYJdJZ2zCpRqrDhxvQOObEDw6vfBFBX6tGdW9UD3XvTfde9O9UP0jVH92rafbHcu8QvvbuDXYAWdbAIKB0nmoTRH-cJmSqps7Ipcb7qMocf3vAHr69NK_xDe6S5Pl</recordid><startdate>20040515</startdate><enddate>20040515</enddate><creator>Freston, J. W.</creator><creator>Pilmer, B. L.</creator><creator>Chiu, Y.‐L.</creator><creator>Wang, Q.</creator><creator>Stolle, J. C.</creator><creator>Griffin, J. S.</creator><creator>Lee, C. Q.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040515</creationdate><title>Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole</title><author>Freston, J. W. ; Pilmer, B. L. ; Chiu, Y.‐L. ; Wang, Q. ; Stolle, J. C. ; Griffin, J. S. ; Lee, C. Q.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4452-6c2f05de367dce4ac4276dac0a87fbde72eed5ffae2a230b4e6d6d34f7bca63c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>2-Pyridinylmethylsulfinylbenzimidazoles</topic><topic>Administration, Oral</topic><topic>Anti-Ulcer Agents - administration & dosage</topic><topic>Anti-Ulcer Agents - pharmacokinetics</topic><topic>Anti-Ulcer Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Chlorates</topic><topic>Cross-Over Studies</topic><topic>Digestive system</topic><topic>Drug Carriers</topic><topic>Ethylene Glycol</topic><topic>Female</topic><topic>Gastric Acid - secretion</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Lansoprazole</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Omeprazole - administration & dosage</topic><topic>Omeprazole - analogs & derivatives</topic><topic>Omeprazole - pharmacokinetics</topic><topic>Omeprazole - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Freston, J. W.</creatorcontrib><creatorcontrib>Pilmer, B. L.</creatorcontrib><creatorcontrib>Chiu, Y.‐L.</creatorcontrib><creatorcontrib>Wang, Q.</creatorcontrib><creatorcontrib>Stolle, J. C.</creatorcontrib><creatorcontrib>Griffin, J. S.</creatorcontrib><creatorcontrib>Lee, C. Q.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Freston, J. W.</au><au>Pilmer, B. L.</au><au>Chiu, Y.‐L.</au><au>Wang, Q.</au><au>Stolle, J. C.</au><au>Griffin, J. S.</au><au>Lee, C. Q.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2004-05-15</date><risdate>2004</risdate><volume>19</volume><issue>10</issue><spage>1111</spage><epage>1122</epage><pages>1111-1122</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Aim : To compare the pharmacokinetics and pharmacodynamics of lansoprazole 30 mg administered intravenously in 0.9% NaCl or in polyethylene glycol, or orally.
Methods : Twenty‐nine subjects received lansoprazole orally on days 1–7 and intravenous lansoprazole in NaCl on days 8–14. Blood samples were collected on days 1, 7, 8 and 14. Fasting basal acid output and pentagastrin‐stimulated maximal acid output were determined on days −1, 8, 9 and 15. Thirty‐six different subjects received one of four regimen sequences: intravenous lansoprazole in NaCl, intravenous in polyethylene glycol, per orally, or intravenous placebo, each for 5 days. Twenty‐four hour intragastric pH was recorded on days 1 and 5.
Results : Intravenous and per oral lansoprazole for 7 days produced equivalent basal acid output and maximal acid output suppression. Pharmacokinetics and mean pH values with intravenous lansoprazole in NaCl or polyethylene glycol were equivalent. Both produced mean pH and percentages of time pH above 3, 4, 5 and 6 that were significantly greater than did per orally.
Conclusions : Intravenous lansoprazole inhibits acid secretion as effectively in NaCl as in polyethylene glycol, and its onset of action is faster than per oral lansoprazole.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>15142201</pmid><doi>10.1111/j.1365-2036.2004.01942.x</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2004-05, Vol.19 (10), p.1111-1122 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71924686 |
| source | MEDLINE; IngentaConnect Free/Open Access Journals; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | 2-Pyridinylmethylsulfinylbenzimidazoles Administration, Oral Anti-Ulcer Agents - administration & dosage Anti-Ulcer Agents - pharmacokinetics Anti-Ulcer Agents - pharmacology Biological and medical sciences Chlorates Cross-Over Studies Digestive system Drug Carriers Ethylene Glycol Female Gastric Acid - secretion Gastroenterology. Liver. Pancreas. Abdomen Humans Infusions, Intravenous Lansoprazole Male Medical sciences Omeprazole - administration & dosage Omeprazole - analogs & derivatives Omeprazole - pharmacokinetics Omeprazole - pharmacology Pharmacology. Drug treatments |
| title | Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T12%3A28%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20pharmacokinetics%20and%20pharmacodynamics%20of%20intravenous%20lansoprazole&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Freston,%20J.%20W.&rft.date=2004-05-15&rft.volume=19&rft.issue=10&rft.spage=1111&rft.epage=1122&rft.pages=1111-1122&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/j.1365-2036.2004.01942.x&rft_dat=%3Cproquest_cross%3E71924686%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71924686&rft_id=info:pmid/15142201&rfr_iscdi=true |